TP53 and cancer: Cancer surveillance, according to the Toronto Protocol, is recommended for both carriers of the TP53 variant with a history of cancer and for asymptomatic relatives, who might be potential carriers of the TP53 variants, aiming to intercept the early occurrence of tumors.